Knight Therapeutics (TSX:GUD) Owner Earnings per Share (TTM): 0.74 (As of Jun. 2026) — 98% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:GUD Knight Therapeutics Inc TSX:GUD
74 GF Score
Price C$9.32
GF Value C$9.22
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Knight Therapeutics Owner Earnings per Share (TTM)?

Knight Therapeutics TSX:GUD +1.19% 74 Owner Earnings per Share (TTM) is 0.74 as of Jun. 2026, which is 98% below its 10-year median of 30.85. GuruFocus rates TSX:GUD with a GF Score™ of 74/100 and a GF Value™ of C$9.22 (Fairly Valued). The stock has 4 warning signs investors should review. Among 464 Drug Manufacturers companies, Knight Therapeutics ranks better than 71.98% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Knight Therapeutics's Owner Earnings per Share (TTM) ended in Jun. 2026 was C$0.74. It's Price-to-Owner-Earnings ratio for today is 12.59.


The historical rank and industry rank for Knight Therapeutics's Owner Earnings per Share (TTM) or its related term are showing as below:

TSX:GUD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.32   Med: 30.85   Max: 731.82
Current: 12.68


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Knight Therapeutics was 731.82. The lowest was 8.32. And the median was 30.85.


TSX:GUD's Price-to-Owner-Earnings is ranked better than
71.98% of 464 companies
in the Drug Manufacturers industry
Industry Median: 23.49 vs TSX:GUD: 12.68

Knight Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was C$-0.03. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was C$0.15. It's PE Ratio (TTM) ratio for today is 62.13.

Knight Therapeutics's EPS without NRI for the three months ended in Jun. 2026 was C$0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was C$0.15. It's PE Ratio without NRI ratio for today is 63.84.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Knight Therapeutics Owner Earnings per Share (TTM) Related Terms


Knight Therapeutics Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Owner Earnings per Share (TTM) Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.39 -0.56 -0.25 -0.14

Knight Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.39 -0.14 0.25 0.74

TSX:GUD vs ZTS: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Price-to-Owner-Earnings falls into.


TSX:GUD
74GF Score
Knight Therapeutics Inc TSX:GUD
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Knight Therapeutics's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 14.9
Depreciation, Depletion and Amortization 64.0
Change In Deferred Tax 4.4
5Y Average of Maintenance Capital Expenditure 21.5
Change In Working Capital 10.3
Shares Outstanding (Diluted Average) 98.2

1. Start with "Net Income" from income statement. Knight Therapeutics's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was C$14.9 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Knight Therapeutics's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 was C$64.0 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Knight Therapeutics's Change In Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 was C$4.4 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = C$21.5 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Knight Therapeutics's 5-Year Average Maintenance Capital Expenditure = C$21.5 Mil

5. "Change In Working Capital" is from cashflow statement. Knight Therapeutics's Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 was C$10.3 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Knight Therapeutics's Shares Outstanding (Diluted Average) for the months ended in Jun. 2026 was 98.199 Mil.

Knight Therapeutics's Onwer Earnings Per Share for Jun. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 14.871 +64.046+4.438
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-21.472801568865+10.269)/98.199
=0.74

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=9.32/0.74
=12.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 0.74 mean?
Knight Therapeutics (TSX:GUD) has a Owner Earnings per Share (TTM) of 0.74 as of Jun. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Knight Therapeutics. This is 98% below median its historical median of 30.85. Over the past decade, Knight Therapeutics' Owner Earnings per Share (TTM) has ranged from 8.32 to 731.82. According to the industry distribution chart, Knight Therapeutics ranks #130 out of 464 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is Knight Therapeutics' Owner Earnings per Share (TTM) too high?
Knight Therapeutics' current Owner Earnings per Share (TTM) of 0.74 is 98% below median its 10-year median of 30.85. Over the past 10 years, this metric has ranged from a low of 8.32 to a high of 731.82. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.49. Knight Therapeutics' value of 0.74 is 96.8% below this industry median. Based on the distribution chart, Knight Therapeutics ranks #130 out of 464 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Owner Earnings per Share (TTM) compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #130 out of 464 companies for Owner Earnings per Share (TTM). This puts Knight Therapeutics in the upper half of its industry. The industry median Owner Earnings per Share (TTM) is 23.49. Knight Therapeutics' value of 0.74 is 96.8% below this benchmark. Historically, Knight Therapeutics' own Owner Earnings per Share (TTM) has ranged from 8.32 to 731.82 over the past decade. While the company's 10-year median is 30.85 vs. the industry median of 23.49, Knight Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.49, based on 464 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current Owner Earnings per Share (TTM) of 0.74 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Knight Therapeutics. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current Owner Earnings per Share (TTM) is 0.74, which is 98% below median its own 10-year median of 30.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Fairly Valued. The stock's GF Value™ is C$9.22, compared to a current price of C$9.32 — trading 1.1% above its estimated fair value. The current Owner Earnings per Share (TTM) is 0.74, which is 98% below median its 10-year median of 30.85 and 96.8% below the Drug Manufacturers industry median of 23.49. Knight Therapeutics' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current Owner Earnings per Share (TTM) is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of C$9.32 is trading 1.1% above its estimated GF Value™ of C$9.22. GuruFocus considers Knight Therapeutics to be Fairly Valued.

Key valuation signals for TSX:GUD:

  • Owner Earnings per Share (TTM): 0.74 (98% below median its 10-year median of 30.85)
  • GF Value™: C$9.22 vs. price of C$9.32 (1.1% above fair value)
  • GF Score™: 74/100 with 4 warning signs
  • Industry Position: 96.8% below the Drug Manufacturers median (#130 of 464)

No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges KHTRF:USA
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
74GF Score

Get the complete analysis for TSX:GUD

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.32
Price
C$9.22
GF Value